Journal article

Trials in type 1 diabetes: Antigen-specific therapies

Ken T Coppieters, Leonard C Harrison, Matthias G von Herrath

Clinical Immunology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2013


Type 1 diabetes (T1D) results from an aberrant immunological response against the insulin-producing beta cells in the islets of the pancreas. The ideal therapy would restore immune balance in a safe and lasting fashion, stopping the process of beta cell decay. The efficacy of immune suppressive agents such as cyclosporin underscores the notion that T1D can in principle be prevented, albeit at an unacceptable long-term safety risk. Immune modulatory drugs such as monoclonal anti-CD3 antibody, on the other hand, have recently had rather disappointing results in phase 3 trials, possibly due to inadequate dosing or choice of inappropriate endpoints. Therefore, it is argued that striking the righ..

View full abstract

University of Melbourne Researchers